Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Secondary Traumatic Stress
Interventions: Resiliance Alliance, Secondary traumatic stress training; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Brooklyn, New York • New York, New York • Staten Island, New York + 1 more

Conditions: Small Cell Lung Cancer
Interventions: LY2523355, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Torrington, Connecticut • Athens, Georgia • Marietta, Georgia + 5 more

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Burbank, California • Encinitas, California • Fresno, California + 5 more

Conditions: Drug Interactions
Interventions: BAY86-9766, Ketoconazole; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pregnancy
Interventions: Fetal Monitoring Device, Investigational Fetal Monitoring Device; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Healthy, Dermatitis, Atopic
Interventions: LY3844583, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pain, Postoperative
Interventions: Breg Pain Care 3000 Catheter, Bupivicaine 0.5%, Placebo; Device · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 15 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bipolar Disorder
Interventions: Continuous Theta Burst Stimulation (cTBS), Intermittent Theta Burst Stimulation (iTBS); Device
Lead sponsor: Mary Phillips, MD MD (Cantab); Other
Eligibility: 18 Years to 35 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type1diabetes, Insulitis, Pancreas Inflamed
Interventions: Definity Suspension for Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pneumonia, Urinary Tract Infection, Antibiotic Stewardship, Care Transition
Interventions: ROAD Home Intervention; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: COVID-19
Interventions: Licensed or EUA SARS-CoV-2 vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York + 6 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA); Genetic
Lead sponsor: Olix Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more

Conditions: Generalized Anxiety Disorder
Interventions: Cognitive Behavioral Therapy, Venlafaxine XR; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Tolvaptan, Hypertonic saline infusion; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: NHT102, DryNeb; Drug · Device
Lead sponsor: Nob Hill Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions: Sofosbuvir/velpatasvir (Epclusa®); Drug
Lead sponsor: Jennifer Havens; Other
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Hazard, Kentucky

Conditions: Acute Myeloid Leukemia
Interventions: Tagraxofusp, Venetoclax, Azacitidine; Drug
Lead sponsor: Stemline Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 24
States / cities: Los Angeles, California • Stanford, California • Miami, Florida + 17 more

Conditions: Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions: Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling; Other · Behavioral · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Growth Hormone Deficiency
Interventions: Growth hormone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Heart Disease in Children, Hypoxia, Neurodevelopmental Disorders, Complex Congenital Heart Disease
Interventions: Single Arm, Neonatal Neurobehavioral Scale; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 0 Years to 52 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: San Francisco, California • Washington D.C., District of Columbia • Scarborough, Maine + 1 more

Conditions: Pediatric Osteosarcoma
Interventions: Cyclophosphamide, Fludarabine, Mesna, Apheresis, SJCARB7H3_41BBL infusion; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy Volunteer
Interventions: ABBV-1451, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Search by objective public record fields.

The Resilience Alliance

A Study for Participants With Small-Cell Lung Cancer

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

Maternal Fetal Device Performance Singleton

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions

Examining the Effect of EEG-guided Theta Burst Stimulation in Bipolar Disorder

Pancreas Ultrasound Imaging in type1 Diabetes

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Reducing Overuse of Antibiotics at Discharge Home

Multisite Observational Maternal and Infant Study for COVID-19

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Combined Treatment for Generalized Anxiety Disorder (GAD)

Effects of Tolvaptan in Healthy Adults

Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

The Kentucky Viral Hepatitis Treatment Study

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior

Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults